title: [Clinical investigation of bisphosphonate-related osteonecrosis of the jaws].
abstract: We examined the clinical features of bisphosphonate(BP)-related osteonecrosis of the jaws(BRONJ), a serious complication resulting from intravenous BP treatment for multiple myeloma and malignant tumors with bone metastasis. We retrospectively reviewed the medical records of 36 patients who received intravenous BP therapy for the above-mentioned conditions, at Sapporo Medical University Hospital between July 2006 and October 2008. BP therapy caused BRONJ in 7 of 24 patients, but did not affect the bones of the other 17 patients. The other 12 of the 36 patients involved in the study were prescribed BP only after they had undergone an oral examination and treatment for dental inflammation. Of these patients, 7 developed BRONJ with BP treatment, after tooth extraction or acute dental inflammation. Treating dental inflammation before prescribing BP prevented the development of BRONJ. BRONJ is highly intractable and does not resolve with the standard treatment for osteomyelitis. Therefore, preventive therapy, which can be achieved by cooperation between medical doctors and dentists, is currently the most effective strategy for BRONJ. Conservative treatment with antibiotics may also be useful for maintaining or improving the quality of life of BRONJ patients.
authors.affiliation: Dept. of Oral Surgery, Sapporo Medical University School of Medicine.
authors.forename: Hironari
authors.initials: H
authors.lastname: Dehari
authors.forename: Kei
authors.initials: K
authors.lastname: Tomihara
authors.forename: Megumi
authors.initials: M
authors.lastname: Ueda
authors.forename: Makoto
authors.initials: M
authors.lastname: Shimanishi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ono
authors.forename: Takanori
authors.initials: T
authors.lastname: Sasaki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Igarashi
authors.forename: Kaori
authors.initials: K
authors.lastname: Shiratori
authors.forename: Masato
authors.initials: M
authors.lastname: Abe
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ogi
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamori
authors.forename: Akihiro
authors.initials: A
authors.lastname: Miyazaki
authors.forename: Itaru
authors.initials: I
authors.lastname: Nagai
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Hiratsuka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D012189:Retrospective Studies
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates